London, 04 March 2015: TechNavio, the independent tech-focused global research firm, has published a report on the Global CD Market 2015-2019, which is expected to grow at a CAGR of 2.84 percent during the forecast period of 2014-2019.
“Current anti-TNF drugs available for the treatment of CD are promising but provide symptomatic relief only. Though the etiology and pathophysiology of CD have been extensively researched, these drugs are not effective enough to induce remission and permanently cure the disease,” says Faisal Ghaus, Vice President of TechNavio.
“Most of the unmet needs are based on efficacy and safety issues such as immunogenicity, loss of response, and adverse effects of the drugs. This necessitates reliable diagnostics tools and specific CD biomarkers.”
Key Market Drivers
- Increased Prevalence of CD
- Significant Unmet Medical Needs
- Promising Drug Pipeline
- Launch of New Drugs
Key Market Trends
- Strategic Collaborations
- Emergence of Biosimilars
- Increased Use of Biologics
Key Market Vendors
- AbbVie Inc.
- AstraZeneca plc
- Biogen Idec Inc.
- Johnson & Johnson
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
